Analysts Expect G1 Therapeutics, Inc. (NASDAQ:GTHX) Will Announce Earnings of -$1.04 Per Share

Brokerages predict that G1 Therapeutics, Inc. (NASDAQ:GTHXGet Rating) will report earnings per share (EPS) of ($1.04) for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for G1 Therapeutics’ earnings. The lowest EPS estimate is ($1.17) and the highest is ($0.97). G1 Therapeutics posted earnings of ($0.94) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 10.6%. The company is expected to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that G1 Therapeutics will report full-year earnings of ($3.87) per share for the current year, with EPS estimates ranging from ($4.19) to ($3.55). For the next year, analysts anticipate that the business will report earnings of ($2.87) per share, with EPS estimates ranging from ($3.38) to ($2.33). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that follow G1 Therapeutics.

G1 Therapeutics (NASDAQ:GTHXGet Rating) last issued its quarterly earnings results on Wednesday, May 4th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.17). G1 Therapeutics had a negative return on equity of 107.75% and a negative net margin of 708.20%. During the same period last year, the business earned ($0.65) earnings per share.

A number of equities research analysts have commented on GTHX shares. Needham & Company LLC reiterated a “buy” rating and set a $44.00 target price on shares of G1 Therapeutics in a report on Thursday, April 14th. Zacks Investment Research upgraded shares of G1 Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, May 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $67.00 price objective on shares of G1 Therapeutics in a research report on Friday, June 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $36.43.

G1 Therapeutics stock opened at $5.09 on Thursday. The stock has a 50-day simple moving average of $5.84 and a 200-day simple moving average of $8.64. The company has a debt-to-equity ratio of 0.76, a quick ratio of 5.73 and a current ratio of 5.96. The company has a market capitalization of $217.39 million, a P/E ratio of -1.26 and a beta of 2.04. G1 Therapeutics has a fifty-two week low of $4.25 and a fifty-two week high of $24.12.

Hedge funds have recently made changes to their positions in the company. Royal Bank of Canada boosted its position in shares of G1 Therapeutics by 69.0% during the 3rd quarter. Royal Bank of Canada now owns 5,254 shares of the company’s stock valued at $71,000 after acquiring an additional 2,145 shares during the last quarter. Ensign Peak Advisors Inc acquired a new stake in G1 Therapeutics in the fourth quarter worth about $79,000. Point72 Hong Kong Ltd acquired a new stake in shares of G1 Therapeutics during the first quarter worth about $83,000. Beacon Pointe Advisors LLC acquired a new stake in shares of G1 Therapeutics during the first quarter worth about $87,000. Finally, BNP Paribas Arbitrage SA lifted its holdings in G1 Therapeutics by 479.1% in the third quarter. BNP Paribas Arbitrage SA now owns 7,772 shares of the company’s stock valued at $104,000 after acquiring an additional 6,430 shares during the period. Hedge funds and other institutional investors own 61.89% of the company’s stock.

About G1 Therapeutics (Get Rating)

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.

Read More

Get a free copy of the Zacks research report on G1 Therapeutics (GTHX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for G1 Therapeutics (NASDAQ:GTHX)

Want More Great Investing Ideas?

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.